Laura M. Kops
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Laura M. Kops has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Adrian Liston
The Babraham Institute, Immunology Programme, Cambridge, UK
1 shared publication - Alvaro R. Hernandez
Department of Pathology, University of Cambridge, Cambridge, UK
1 shared publication - Amy Dashwood
Department of Pathology, University of Cambridge, Cambridge, UK
1 shared publication - Arman Ghodsinia
Department of Pathology, University of Cambridge, Cambridge, UK
1 shared publication - Ekhlas Rahman
National Heart & Lung Institute, Imperial College London, London, UK
1 shared publication Fran Naranjo
Lymphocyte Signalling Department, Babraham Institute Babraham Research Campus, Cambridge, UK
1 shared publication
Latest Publications
- 17 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (118) , eadv7969
Gene delivery of immunomodulatory cytokines to the lung preserves respiratory function during inflammatory challenge
Respiratory infections that result in severe and life-threatening immune-mediated respiratory decline are a major public health issue. Controlling local respiratory immune reactions without the use of systemic immunosuppressants remains an unmet clinical challenge. We developed a gene delivery system to express anti-inflammatory cytokines in the lung, which reestablishes local immune homeostasis without triggering systemic effects. Using an adeno-associated vector cargo system (AAV6.2- CC10 ), we induced production of interleukin-2 (IL-2), IL-1 receptor antagonist (IL-1RA), and IL-10 in situ in the lung microenvironment, with no detectable expression or immunological deviation in the peripheral immune system. We demonstrate the effective potential of IL-2, IL-1RA, and IL-10 as immunomodulatory cargos in severe infectious challenge, which reduced respiratory pathology after influenza-associated pulmonary aspergillosis. Thus, the AAV6.2- CC10 platform enables targeted delivery of biologics to the lung, modulates the lung environment, and improves pathology without inducing systemic immune reactions.
- 17 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (118) , eadv7969
Gene delivery of immunomodulatory cytokines to the lung preserves respiratory function during inflammatory challenge
Respiratory infections that result in severe and life-threatening immune-mediated respiratory decline are a major public health issue. Controlling local respiratory immune reactions without the use of systemic immunosuppressants remains an unmet clinical challenge. We developed a gene delivery system to express anti-inflammatory cytokines in the lung, which reestablishes local immune homeostasis without triggering systemic effects. Using an adeno-associated vector cargo system (AAV6.2- CC10 ), we induced production of interleukin-2 (IL-2), IL-1 receptor antagonist (IL-1RA), and IL-10 in situ in the lung microenvironment, with no detectable expression or immunological deviation in the peripheral immune system. We demonstrate the effective potential of IL-2, IL-1RA, and IL-10 as immunomodulatory cargos in severe infectious challenge, which reduced respiratory pathology after influenza-associated pulmonary aspergillosis. Thus, the AAV6.2- CC10 platform enables targeted delivery of biologics to the lung, modulates the lung environment, and improves pathology without inducing systemic immune reactions.